Week of February 28th 2022 | Vol. 11, Issue 9
Events Hosted or Attended by Bourne Partners
March 21-24, 2022 - New York City, NY
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
June 13-16, 2022 - San Diego, CA
October 2022 - Charlotte, NC
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
TRADING COMPS
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
MARKET REPORTS
Insight Into Healthcare Related Industries
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence.
February 22, 2022 - Fierce Biotech
The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests that finally reached the public markets.
Somatus has secured over $325 million in a series E funding round led by Wellington Management Company, placing the value-based kidney care company at a valuation exceeding $2.5 billion.
For patients with chronic conditions, the battle for their own health can’t be won by visiting the doctor a few times a year, according to Omada Health President Wei-Li Shao.

Discover more about the connection between real-world data capture and early access programs, and the role this plays in the approval of life-improving medicines.